Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Design Therapeutics Inc

DSGN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$15.23

▲ +0.59%

Market Cap $953.12M · Vol 145.61K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$953.12M

Small Cap

Div Yield

N/A

EPS Growth

-11.71%

YoY

RSI (14)

49.50

Momentum

Beta

1.67

vs Market

52W High

$17.20

11.45% below

52W Low

$5.28

188.45% above

Volume

145.61K

Avg 160.34K

P/B

2.67

Price-to-book

ROE

N/A

Return on equity

Free Float

65.37%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Design Therapeutics Inc (DSGN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DSGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.93%

+8.86%

+45.60%

+51.54%

YTD

+62.37%

+161.68%

+474.72%

-16.87%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-69,792,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-29.18% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.67
P/FCF	N/A
EPS Growth	-11.71%
Outstanding Shares	62.58M

Technical Indicators

50-Day SMA	$14.11
200-Day SMA	$11.68
RSI (14)	49.50
Beta	1.67
52-Week High	$17.20
52-Week Low	$5.28

Volume Today	145.61K
Avg Daily Volume (30D)	160.34K
Relative Volume	0.91x
Volatility (10D)	28.60
Volatility (30D)	36.86
Free Float	65.37%

Analyst Consensus

BUY

Current Price $15.23

Mean Target $21.00

52W Low$5.28 52W High$17.20

Current

Target

$5.28 $17.20

Current Analyst target

+37.89% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00SNC49W7

ISINUS25056L1035

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.82% RVMD Revolution Medicines Inc -1.29% ONC BeOne Medicines AG -1.89% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +3.62%

Company Profile

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.